FDA Grants Breakthrough Device Designation for Phospho-Tau 217 Blood Test for Alzheimer's Disease

The FDA has recognized the phospho-Tau 217 (p-Tau 217) blood test, developed by Quanterix Corporation, with a breakthrough device designation. This designation is aimed at products that promise more effective diagnosis of life-threatening diseases with unmet medical needs. The p-Tau 217 test is a significant advancement in the diagnosis of Alzheimer's disease (AD), offering a non-invasive alternative to traditional methods such as positron emission tomography (PET) and lumbar puncture for cerebrospinal fluid (CSF) biomarkers.

p-Tau 217 stands out as a top-performing biomarker for AD pathology, capable of accurately diagnosing amyloid pathology through ultrasensitive assessments. This innovation enhances clinical AD diagnostics by providing a simpler, more accessible testing method for patients. The test is intended for use in patients presenting cognitive impairment and being evaluated for AD risk, though it is not a stand-alone diagnostic tool. Results should be interpreted alongside other diagnostic methods to ensure an accurate diagnosis.

Masoud Toloue, CEO of Quanterix, emphasized the importance of early detection in developing effective care strategies and improving patient outcomes. The breakthrough designation marks a significant step towards establishing a global testing infrastructure for AD, highlighting the value of accessible, non-invasive testing methods.

The p-Tau 217 test has been clinically validated in a study involving 500 participants with varying cognitive statuses, demonstrating an overall accuracy greater than 90%. This performance meets the stringent requirements set by the National Institute on Aging and Alzheimer Association Revised Criteria for Diagnosis and Staging of AD.

Despite its success, the breakthrough designation does not guarantee a shortened review or approval process by the FDA. However, the p-Tau 217 test represents a promising development in the clinical workflow for diagnosing and treating AD, potentially reducing reliance on PET and CSF testing and simplifying the diagnostic process.

Quanterix is committed to making the p-Tau 217 test available worldwide, aiming to improve access to life-changing diagnostics and treatments for individuals and families affected by AD.